[go: up one dir, main page]

WO1992004015A3 - Regulation of t-cell proliferation via a novel 5ht1a receptor - Google Patents

Regulation of t-cell proliferation via a novel 5ht1a receptor Download PDF

Info

Publication number
WO1992004015A3
WO1992004015A3 PCT/US1991/006176 US9106176W WO9204015A3 WO 1992004015 A3 WO1992004015 A3 WO 1992004015A3 US 9106176 W US9106176 W US 9106176W WO 9204015 A3 WO9204015 A3 WO 9204015A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferation
regulation
novel
5ht1a receptor
proliferation via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006176
Other languages
French (fr)
Other versions
WO1992004015A2 (en
Inventor
Thomas Martin Aune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Priority to JP3517820A priority Critical patent/JPH06503816A/en
Publication of WO1992004015A2 publication Critical patent/WO1992004015A2/en
Publication of WO1992004015A3 publication Critical patent/WO1992004015A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of regulating proliferation of activated T cells exhibiting a 5HT1a receptor by introducing a sufficient amount of agonists or antagonists to either increase or decrease T cell proliferation. The basis for regulating cell proliferation may be (1) via the 5HT receptor, (2) via serotonin synthesis inhibition and/or (3) via serotonin stimulation of CD8+ subpopulations of activated T cells.
PCT/US1991/006176 1990-09-04 1991-09-04 REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR Ceased WO1992004015A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3517820A JPH06503816A (en) 1990-09-04 1991-09-04 Regulation of T cell proliferation through a novel 5HT1a receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57871090A 1990-09-04 1990-09-04
US578,710 1990-09-04

Publications (2)

Publication Number Publication Date
WO1992004015A2 WO1992004015A2 (en) 1992-03-19
WO1992004015A3 true WO1992004015A3 (en) 1992-04-16

Family

ID=24313971

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1991/006175 Ceased WO1992004014A2 (en) 1990-09-04 1991-09-04 REGULATION OF NEOPLASTIC CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR
PCT/US1991/006176 Ceased WO1992004015A2 (en) 1990-09-04 1991-09-04 REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006175 Ceased WO1992004014A2 (en) 1990-09-04 1991-09-04 REGULATION OF NEOPLASTIC CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR

Country Status (5)

Country Link
EP (2) EP0555231A1 (en)
JP (2) JPH06500775A (en)
AU (2) AU8499891A (en)
CA (2) CA2090689A1 (en)
WO (2) WO1992004014A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461054A (en) * 1993-12-09 1995-10-24 Bayer Aktiengesellschaft Anthracene-spiro-pyrrolindines
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
US5409932A (en) * 1993-12-09 1995-04-25 Bayer Ag Piperazine-substituted pyrroloanthracenes
WO1996001106A1 (en) * 1994-07-06 1996-01-18 Bo Arne Hofmann Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
WO1996001107A1 (en) * 1994-07-06 1996-01-18 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EP0813878B1 (en) * 1996-06-17 2002-02-06 Mitsubishi Chemical Corporation Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
CA2443050A1 (en) 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
NZ580495A (en) 2007-04-13 2011-05-27 Southern Res Inst Use of anti-angiogenic agents and methods of use, particulary amiodarone for inhibiting or reducing angiogenesis
JP2023539775A (en) * 2020-09-02 2023-09-19 ワイゼットセラピューティク パフォーマンス リミテッド Cell compositions and methods of use for the treatment of diseases, disorders or conditions
CN113599370B (en) * 2021-08-03 2023-12-08 复旦大学附属肿瘤医院 Application of 8-OH-DPAT and derivatives thereof in preparation of antitumor drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065375A1 (en) * 1989-08-21 1991-02-22 Richard J. Sharpe Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Eur. J. Pharmacol., vol. 170, no. 1/2, October 1989, Elsevier Science Publishers B.V., Amsterdam (NL), M. Pranzatelli et al.: "Identification of 5-HT1A recognition sites in human ganglioneuroblastoma", pages 127-128, see the whole article *
J. Immunol., vol. 145, no. 6, 15 September 1990, Baltimore (US), T. Aune et al.: "Serotonin-activated signal transduction via serotonin receptors on Jurkat cells", pages 1826-1831, see the whole article *
N. Engl. J. Med., vol. 277, no. 21, 23 November 1967, Boston (US), K. Engelman et al.: "Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome", pages 1103-1108, see page 1108, lines 13-32 *
Proc. Natl. Acad. Sci, USA, vol. 82, no. 2, January 1985, Washington DC, (US) R. Todd et al.: "Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child", pages 612-616, see the abstract *

Also Published As

Publication number Publication date
WO1992004014A2 (en) 1992-03-19
AU8848291A (en) 1992-03-30
EP0547172A1 (en) 1993-06-23
CA2090689A1 (en) 1992-03-05
AU8499891A (en) 1992-03-30
CA2090688A1 (en) 1992-03-05
JPH06503816A (en) 1994-04-28
EP0555231A1 (en) 1993-08-18
WO1992004015A2 (en) 1992-03-19
WO1992004014A3 (en) 1992-05-14
JPH06500775A (en) 1994-01-27

Similar Documents

Publication Publication Date Title
SG48225A1 (en) Styryl-substituted heteroaryl compounds which inhibit for receptor tyrosine kinase
MD1616F2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
WO1992004015A3 (en) Regulation of t-cell proliferation via a novel 5ht1a receptor
MY118556A (en) Catalytic composition suitable for the fischer-tropsch process
AU558375B2 (en) 6-(7-)-oxy-trans-1,2,3,4,4a,5,10,10a-octahydrobenzo (g)quinolines
ES8801789A1 (en) Indole derivative
CA2137793A1 (en) Crystallization of m-csf
MD1632F2 (en) Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
AU9648098A (en) Adenosine a3 receptor antagonists
HU9203515D0 (en) Method for producing neuron protective indolones, their analogous derivatives and pharmaceutical preparatives containing these compounds
AU1710183A (en) Pyridine-n-oxide derivatives
ATE238771T1 (en) PROCESS FOR PRODUCTION OF SOLUBLE DISTRIBUTION SYSTEMS USING VOLATILE SALTS
AU1208397A (en) Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
GR3034498T3 (en) Substituted benzylaminoquinuclidines as substance p antagonists.
EP0354777A3 (en) 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
IL99571A0 (en) Process for the preparation of water soluble camptothecin analogs,compounds prepared by said process,and methods of use thereof
EP0351112A3 (en) Photochromic compound, process for production thereof, use thereof and composition containing said photochromic compound
CA2340999A1 (en) 5-arylindole derivatives
MX9801890A (en) Novel human nk3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them.
TW248566B (en)
ES2000368A6 (en) Substituted-di-t-butylphenols.
EP0081923A3 (en) 2-(trisubstituted phenylimino)-imidazolines
DK616084A (en) INACTIVE BINDING POLYCAPROLACTON BASED ON AN ORAL ORAL SUBSTANCES AND PROCEDURE FOR PREPARING A MIXTURE CONTAINING THE BINDING
AU2736495A (en) Agonists and antagonists of the nicotinic acetylcholine receptors of insects to control endoparasites
ES8800214A1 (en) Substituted benzimidazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use as inhibitors of gastric-acid secretion.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991918533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2090689

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991918533

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991918533

Country of ref document: EP